[Effect of intra-arterial and local administration of MCNU on cerebral malignant gliomas].
Twenty-six patients with cerebral malignant glioma (7 cases of astrocytoma Grade 3, and 19 of astrocytoma Grade 4) were treated by intra-arterial and local administration of MCNU. Nineteen patients were treated in combination with local radiation in a dose of 60 Gy. Intra-arterial administration of MCNU was performed by puncture of the ipsilateral common carotid artery and injection of 25mg of MCNU in 20 ml of physiological saline. Local administration of MCNU was performed by puncture of the Ommaya reservoir placed within the cavity after tumor resection. Objective tumor regression was observed on computerized tomography (CT) scans after intra-arterial and/or local administration of MCNU combined with radiotherapy in three of seven patients who had evaluable enhanced lesions on CT after surgery. It was also observed after chemotherapy alone in one of three patients with evaluable lesions. The response rate was 42.9% among patients treated with MCNU in combination with radiotherapy, and 33.3% in patients treated with MCNU alone. In two patients, local administration of MCNU induced brain edema, which was transient and caused no neurological sequelae. One patient suffered mild thrombocytopenia after seven intra-arterial doses of MCNU, however, no myelosuppression requiring administration of gamma-GCSF or blood transfusions was observed. These findings suggest that intra-arterial and local administration of MCNU can be expected to serve as effective and non-myelosuppressive chemotherapy in patients with cerebral malignant gliomas.
Watanabe
M
M
Dept. of Nurosurgery, Brain Research Institute, Niigata University.
Takeda
N
N
Tanaka
R
R
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001929:Brain Edema / Q000139:chemically induced; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005909:Glioblastoma / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D015918:Infusion Pumps, Implantable; D007269:Injections, Intra-Arterial; D015552:Injections, Intralesional; D008099:Liver / Q000187:drug effects; D009607:Nitrosourea Compounds / Q000008:administration & dosage* / Q000009:adverse effects
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; C020766:ranimustine